Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Accord-UK Ltd (Trading style: Accord), Whiddon Valley, Barnstaple, Devon, EX32 8NS
Raporsin XL 4mg Prolonged-release Tablets.
| Pharmaceutical Form |
|---|
|
Prolonged-release tablet. White, round, biconvex tablets with bossing “DL”. |
Each prolonged-release tablet contains: 4 mg doxazosin (as mesilate).
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Doxazosin |
Doxazosin is a potent and selective post-junctional alpha-1-adrenoceptor antagonist. This action results in a decrease in systemic blood pressure. |
| List of Excipients |
|---|
|
Tablet core: Polyethylene oxide Tablet coat: Methacrylic acid – ethyl acrylate copolymer (1:1) Dispersion 30 per cent |
PVC/PVDC/aluminium blister.
Pack sizes: 10, 28, 30, 50, 90, 98 and 100 prolonged-release tablets.
Not all pack sizes may be marketed.
Accord-UK Ltd (Trading style: Accord), Whiddon Valley, Barnstaple, Devon, EX32 8NS
PL 0142/1184
12.02.2009
Renewal Approved 06.02.2014
| Drug | Countries | |
|---|---|---|
| RAPORSIN | Ireland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
